381 related articles for article (PubMed ID: 36939214)
1. Peptide emulsions in incomplete Freund's adjuvant create effective nurseries promoting egress of systemic CD4
Melssen MM; Fisher CT; Slingluff CL; Melief CJM
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36939214
[TBL] [Abstract][Full Text] [Related]
2. A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients.
Melssen MM; Petroni GR; Chianese-Bullock KA; Wages NA; Grosh WW; Varhegyi N; Smolkin ME; Smith KT; Galeassi NV; Deacon DH; Gaughan EM; Slingluff CL
J Immunother Cancer; 2019 Jun; 7(1):163. PubMed ID: 31248461
[TBL] [Abstract][Full Text] [Related]
3. Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment.
Pollack KE; Meneveau MO; Melssen MM; Lynch KT; Koeppel AF; Young SJ; Turner S; Kumar P; Sol-Church K; Mauldin IS; Slingluff CL
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32350119
[TBL] [Abstract][Full Text] [Related]
4. Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity.
Graham BS; McElrath MJ; Keefer MC; Rybczyk K; Berger D; Weinhold KJ; Ottinger J; Ferarri G; Montefiori DC; Stablein D; Smith C; Ginsberg R; Eldridge J; Duerr A; Fast P; Haynes BF;
PLoS One; 2010 Aug; 5(8):e11995. PubMed ID: 20706632
[TBL] [Abstract][Full Text] [Related]
5. Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63).
Slingluff CL; Petroni GR; Chianese-Bullock KA; Wages NA; Olson WC; Smith KT; Haden K; Dengel LT; Dickinson A; Reed C; Gaughan EM; Grosh WW; Kaur V; Varhegyi N; Smolkin M; Galeassi NV; Deacon D; Hall EH
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479025
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist.
Meneveau MO; Petroni GR; Salerno EP; Lynch KT; Smolkin M; Woodson E; Chianese-Bullock KA; Olson WC; Deacon D; Patterson JW; Grosh WW; Slingluff CL
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34035112
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines.
Slingluff CL; Petroni GR; Smolkin ME; Chianese-Bullock KA; Smith K; Murphy C; Galeassi N; Neese PY; Grosh WW; Nail CJ; Ross M; von Mehren M; Haas N; Boisvert ME; Kirkwood JM
J Immunother; 2010; 33(6):630-8. PubMed ID: 20551833
[TBL] [Abstract][Full Text] [Related]
8. Characterization and comparison of innate and adaptive immune responses at vaccine sites in melanoma vaccine clinical trials.
Melssen MM; Pollack KE; Meneveau MO; Smolkin ME; Pinczewski J; Koeppel AF; Turner SD; Sol-Church K; Hickman A; Deacon DH; Petroni GR; Slingluff CL
Cancer Immunol Immunother; 2021 Aug; 70(8):2151-2164. PubMed ID: 33454795
[TBL] [Abstract][Full Text] [Related]
9. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma.
Patel SP; Petroni GR; Roszik J; Olson WC; Wages NA; Chianese-Bullock KA; Smolkin M; Varhegyi N; Gaughan E; Smith KT; Haden K; Hall EH; Gnjatic S; Hwu P; Slingluff CL
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34413169
[TBL] [Abstract][Full Text] [Related]
11. The adjuvant effect of melanin is superior to incomplete Freund's adjuvant in subunit/peptide vaccines in mice.
Cuzzubbo S; Banissi C; Rouchon MS; Tran T; Tanchot C; Tartour E; Carpentier AF
Cancer Immunol Immunother; 2020 Dec; 69(12):2501-2512. PubMed ID: 32561966
[TBL] [Abstract][Full Text] [Related]
12. Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation.
Rahimian S; Fransen MF; Kleinovink JW; Christensen JR; Amidi M; Hennink WE; Ossendorp F
J Control Release; 2015 Apr; 203():16-22. PubMed ID: 25660830
[TBL] [Abstract][Full Text] [Related]
13. Rational Design of T-Cell- and B-Cell-Based Therapeutic Cancer Vaccines.
Li WH; Su JY; Li YM
Acc Chem Res; 2022 Sep; 55(18):2660-2671. PubMed ID: 36048514
[TBL] [Abstract][Full Text] [Related]
14. A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma.
Slingluff CL; Zarour HM; Tawbi HA; Kirkwood JM; Postow MA; Friedlander P; Devoe CE; Gaughan EM; Mauldin IS; Olson WC; Smith KT; Macri MJ; Ricciardi T; Ryan A; Venhaus R; Wolchok JD
Oncoimmunology; 2021 Mar; 10(1):1898105. PubMed ID: 33796406
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients.
Sabbatini P; Tsuji T; Ferran L; Ritter E; Sedrak C; Tuballes K; Jungbluth AA; Ritter G; Aghajanian C; Bell-McGuinn K; Hensley ML; Konner J; Tew W; Spriggs DR; Hoffman EW; Venhaus R; Pan L; Salazar AM; Diefenbach CM; Old LJ; Gnjatic S
Clin Cancer Res; 2012 Dec; 18(23):6497-508. PubMed ID: 23032745
[TBL] [Abstract][Full Text] [Related]
16. Different adjuvanticity of incomplete freund's adjuvant derived from beef or vegetable components in melanoma patients immunized with a peptide vaccine.
Rosenberg SA; Yang JC; Kammula US; Hughes MS; Restifo NP; Schwarz SL; Morton KE; Laurencot CM; Sherry RM
J Immunother; 2010; 33(6):626-9. PubMed ID: 20551834
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Montanide adjuvants, IMS 3012 (Nanoparticle), ISA 206 and ISA 35 (Emulsion based) along with incomplete Freund's adjuvant for hyperimmunization of equines used for production of polyvalent snake antivenom.
Waghmare A; Deopurkar RL; Salvi N; Khadilkar M; Kalolikar M; Gade SK
Vaccine; 2009 Feb; 27(7):1067-72. PubMed ID: 19100805
[TBL] [Abstract][Full Text] [Related]
18. Formulation and characterization of a ten-peptide single-vial vaccine, EP-2101, designed to induce cytotoxic T-lymphocyte responses for cancer immunotherapy.
Beebe M; Qin M; Moi M; Wu S; Heiati H; Walker L; Newman M; Fikes J; Ishioka GY
Hum Vaccin; 2008; 4(3):210-8. PubMed ID: 18382135
[TBL] [Abstract][Full Text] [Related]
19. Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies.
Rezvani K; Yong AS; Mielke S; Jafarpour B; Savani BN; Le RQ; Eniafe R; Musse L; Boss C; Kurlander R; Barrett AJ
Haematologica; 2011 Mar; 96(3):432-40. PubMed ID: 21134985
[TBL] [Abstract][Full Text] [Related]
20. Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors.
Bekaii-Saab T; Wesolowski R; Ahn DH; Wu C; Mortazavi A; Lustberg M; Ramaswamy B; Fowler J; Wei L; Overholser J; Kaumaya PTP
Clin Cancer Res; 2019 Jun; 25(12):3495-3507. PubMed ID: 30804020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
